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Abstract
Background: No studies have been conducted in Greece with the aim of investigating the influence of ethnicity
on the prescribing and treatment outcome of voluntarily admitted inpatients. Most studies conducted in the UK
and the US, both on inpatients and outpatients, focus on the dosage of antipsychotics for schizophrenic patients
and many suffer from significant methodological limitations. Using a simple design, we aimed to assess negative
ethnic bias in psychotropic medication prescribing by comparing discrepancies in use between native and non-
native psychiatric inpatients. We also aimed to compare differences in treatment outcome between the two
groups.
Methods: In this retrospective study, the prescribing of medication was compared between 90 Greek and 63 non-
Greek inpatients which were consecutively admitted into the emergency department of a hospital covering
Athens, the capital of Greece. Participants suferred from schizophrenia and other psychotic disorders. Overall,
groups were compared with regard to 12 outcomes, six related to prescribing and six related to treatment
outcome as assesed by standardised psychometric tools.
Results: No difference between the two ethnic groups was found in terms of improvement in treatment as
measured by GAF and BPRS-E. Polypharmacy, use of first generation antipsychotics, second generation
antipsychotics and use of mood stabilizers were not found to be associated with ethnicity. However, non-Greeks
were less likely to receive SSRIs-SNRIs and more likely to receive benzodiazepines.
Conclusions: Our study found limited evidence for ethnic bias. The stronger indication for racial bias was found in
benzodiazepine prescribing. We discuss alternative explanations and give arguments calling for future research that
will focus on disorders other than schizophrenia and studying non-inpatient populations.
Background
Ethnicity as a form of clinical bias in psychiatric contexts
has long been debated and researched. The effect of eth-
nicity in clinical practice has been investigated in refer-
ence to diagnosis [1] and treatment (i.e. prescribing
practices [2], psychotherapy outcome [3]) - for both in-
patients as well as outpatients. More recently several stu-
dies have identified clinical bias and heightened concern
has been raised, calling for more extensive research on
institutional racism, and the training of staff to address
disparities in both admission and use of mental health
services. It has been shown, for example, that ethnic min-
ority group members tend to be perceived as having
more psychopathological traits compared to other popu-
lation groups and are more likely to be admitted to psy-
chiatric wards [4].
However, findings are relatively inconsistent as several
other studies have identified no such biases among
patients of different ethnicities [5-7]. Research in this
area is extensive and the bulk of studies have focused on
patients with schizophrenia [8-11]. In cases where insti-
tutional bias was identified in the prescribing patterns in
these studies, most researchers focused on antipsychotic
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-FGAs- versus second generation antipsychotics -SGAs)
rather than looking at other categories of drugs. Further
limitations with antipsychotic drug prescribing arise from
the inherent methodological difficulties within empirical
work in this field of inquiry. For instance, Yorston and
Pinney [12] outline the problems of using a standard, and
commonly used method of measuring total antipsychotic
dose in terms of chlorpromazine equivalents. Moreover,
while institutional bias and ethnicity have been investi-
gated thoroughly with regard to primary care of psychia-
tric patients, there are fewer studies on psychiatric
in-patients.
Additionally, the vast majority of the studies come from
the US and the UK [13] and to a lesser extent from other,
developed ‘western countries’. Thus, whereas issues such
as ethnicity and race have been debated for a long time
in these countries, other countries less economically
developed have not contributed to this debate. To our
knowledge there have been no studies in Greece regard-
ing race and ethnicity affecting psychiatric prescribing
practices. This is not surprising as Greece has been up
until recently a fairly homogeneous country. This has
changed and since the late seventies Greece has received
a large amount of immigrants. Initially these were of
Greek origins that returned from countries of the ‘East-
ern bloc ‘. Later, immigrants from the Balkan states
(mainly Albania) arrived. They were followed by immi-
grants of Kurdish, Afghan and African origin.
In this first study of assessing ethnicity as a form of clini-
cal bias in voluntarily admitted inpatients’ treatment, our
aim was to investigate for possible differences with regard
to prescribing practice, focusing on use rather than dosage.
Thus, the design of the study aimed at being simple in
order to minimize the possibility that our findings were
compromised by methodological limitations inherent in
these type of studies. We aimed to investigate for negative
ethnic bias across native and non-native inpatients that
fulfilled the DSM criteria for schizophrenia and other psy-
chotic disorders (schizoaffective and delusional disorder).
Rather than focusing only on antipsychotic medication, we
tested for differences in prescribing for mood stabilizers,
SSRIs-SNRIs, benzodiazepines, drugs which are often
administered to schizophrenic patients. Additionally, we
aimed to compare treatment outcome across ethnic
groups as assessed by two commonly used scales General
Assessment of Functioning (GAF) and the Brief Psychia-
tric Rating Scale (BPRS-E).
Methods
The study was conducted at the Second Psychiatric
Clinic of Athens University Medical School in Attikon
General Hospital which had recently opened. This unit
does not accept involuntary admissions. Our sample
comprised of 153 in-patients admitted consecutively via
the emergency department of the hospital from April
2008 to December 2009. The emergency department is
on call twice a week (Mondays and Thursdays), covering
the area of Attica, with another large psychiatric hospital
which assesses requests for involuntary admissions.
Attica is the most densely populated geographical area
in Greece, including Athens where half of the residents
in Greece live. The age of patients ranged from 19 to 59
years old; 81 were males and 72 females. They were
designated as Greek (N = 90) or non-Greek (N = 63) if
both their parents were either Greek or non-Greek
respectively. Patients from mixed-ethnicity marriages
were excluded from the study. All patients fulfilled the
DSM-IV-TR criteria for schizophrenia and other psy-
chotic disorders (schizoaffective and delusional). Admis-
sion of patients was made on a voluntary basis alone.
No restraint, enforced medication or seclusion was used
for any of the patients.
Based on the relevant literature we checked for several
confounding variables, including length of stay, age,
legal status upon admission, substance misuse upon
admission, prior substance misuse and smoking status
on admission.
Each patient received an initial diagnosis and admission
approval by the two psychiatrists responsible for the
emergency department on the day of admission. Overall,
18 trained psychiatrists participated in this study. The on
call psychiatrists were aware that their clinical judgments
would be used in a study about medication prescribing.
They were blind to the fact that the study explored ethnic
bias in clinical practice. All psychiatrists were of Greek
nationality with both parents Greek.
The social and psychological functioning of patients
was assessed by the Global Assessment of Functioning
(GAF) scale. GAF is widely used in mental health prac-
tice and has established good validity [14,15]. Moreover,
because GAF is meant to assess patients’ functioning
and not their psychiatric symptoms, the brief psychiatric
rating scale-extended version (BPRS-E) [16] was also
used to assess symptom severity on admission and dis-
charge. The BPRS comprises of 24 symptom constructs,
each rated on a 7-point scale of severity. This rating
scale been used extensively with populations with severe
and persistent mental problems and has established
sound reliability and validity
Medication (types and doses of drugs) upon admission
was determined by the two psychiatrists that had agreed
to admit each patient. GAF and BPRS-E ratings upon
admission were conducted by the same two psychia-
trists. Medication on discharge as well as GAF and
BPRS ratings on discharge were determined by the
responsible attending psychiatrist which was one of the
two psychiatrists that had admitted the patient.
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Attikon University General Hospital ethics Committee
and consequently by the Attikon General Hospital
Scientific Committee. Written informed consent was
obtained by the patients. Overall, data were gathered by
the medical and nursing files of the Department as well
as the attending psychiatrist and nursing staff.
Prescribing practice was compared between the groups
with reference to 5 factors:
1. Polypharmacy was defined as the concurrent treat-
ment with more than one psychiatric medication (as
opposed to treatment with one or more antipsychotic
agents [17] employed in most other studies). Thus, in our
study it consisted simply in the sum, in absolute number,
(rather than rated in doses, usually sum of individual % of
the maximum dose allowed) of the different drugs given in
each of the following categories: FGAs, SGAs, mood stabi-
lizers, SSRIs-SNRIs and benzodiazepines. If in one category
more than one drug was given, this would also be counted
(two mood stabilizers, one SGA and two different benzo-
diazepines would make up 5 in our score). In Greece, anti-
psychotic polypharmacy is very widespread and is a
product of poor yet well-meant and standard practice.
Thus we figured that elevated use of antipsychotic poly-
pharmacy in non-Greeks would be difficult to associate
with intended racial behavior. The latter might be better
assessed by the measure adopted in our study, especially as
Greek psychiatrists are well aware of the negative short
and long terms consequences of polypharmacy,
2. Use of FGAs (yes/no)
3. Use of SGAs (yes/no)
4. Use of mood stabilizers (yes/no)
5. Use of SSRI-SNRI. (Yes/no)
6. Use of benzodiazepines (Yes/no)
Thus, we compared six outcomes related to prescrib-
ing and six scale outcomes; differences in BPRS-E and
G A Fo na d m i s s i o n ,o nd i s c h a r g ea n do ni m p r o v e m e n t
as rated by each scale (that consisted of the mean differ-
ences in ratings-discharge mean minus admission mean
for each ethnic group).
In total we tested for twelve two-tailed experimental
hypotheses. Based on the literature we expected to find
some evidence of negative ethnic bias towards the ethnic
minority group members in terms of one or more cate-
gories tested.
Results
Table 1 shows the countries of origin of the non-Greeks
admitted. The vast majority comprises of patients of
Albanian origin, 50, 79% of all non-Greeks.
Table 2 shows the diagnoses and chronicity across the
two groups. Pearson Chi square tests were non-signifi-
cant for both diagnostic category x2(2) = 1,408 p > 0.05
and chronicity x
2 (1) = 0,217 p > 0.05
Table 3 shows the demographic and clinical variables
of the study.
Mann-Whitney tests, and chi-square tests gave no sig-
nificant differences between the groups in smoking status,
age, gender, history of substance misuse, substance misuse
upon admission. All non-Greeks had no forensic status
upon admission compared to 93,3% of Greeks having no
forensic status upon admission x
2 (1) = 4,371 p < 0.05.
For the remaining of the variables the significance
level was adjusted for multiple comparisons by the
Holm-Bonferroni method.
Mann-Whitney tests gave no signficant differences in:
BPRS on admission, BPRS on discharge, BPRS improve-
ment, GAF on admission, GAF on discharge, GAF
improvement ratings, length of stay and polypharmacy
across ethnic groups.
Pearson chi-square tests gave no significant difference
in the use of mood stabilizers, use of FGAs or SGAs
across ethnic groups.
Table 1 Countries of origin among non-Greek Patients
Country of origin Number of patients
Albania 32
Romania 4
Russia 4
Afghanistan 3
Pakistan 3
Bulgaria 3
Moldavia 3
Poland 2
Kazakhstan 2
Tunisia 2
Nigeria 2
Germany 1
Cuba 1
South Africa 1
Table 2 Diagnoses and chronicity across the two ethnic
groups
Participant’s Ethnicity Total
Greek Foreign
Participants’
diagnosis
Schizophrenia 69 51 120
76,70% 81,00% 78,40%
Delusional 12 9 21
13,30% 14,30% 13,70%
Schizoaffective 9 3 12
10,00% 4,80% 7,80%
Chronicity First episode 48 36 84
53,30% 57,10% 54,90%
Chronic patient 42 27 69
46,70% 42,90% 45,10%
Douzenis et al. BMC Psychiatry 2011, 11:66
http://www.biomedcentral.com/1471-244X/11/66
Page 3 of 6Pearson chi square tests gave significant differences
across ethnic groups in: use of SSRIs-SNRIs between the
groups x
2(1) = 27,684 p = 0,00 and use of benzodiazepines
x
2(1) = 18,79, p = 0,00. Correcting for the non-significant
gender imbalance between the two ethnic groups we still
obtained: for use of SSRIs-SNRIs x
2(1) = 32,942 p = 0,00
(and Fisher’s exact p = 0,00), the phi 0,464, with 54,4% of
Greeks non receiving SSRIs-SNRIs as opposed to 96,8% of
non-Greeks; for use of benzodiazepines x2(1) = 17,277 p =
0,00 (and Fisher’s exact p = 0,00), the phi 0,336, with
42,2% of Greeks not receiving benzodiazepines as opposed
to only 11,1 of non-Greeks. In order to attempt to explain
the big differences between SSRI-SNRI and benzodiaze-
pine use between Greek and ethnic minority patients, we
carried out Mann-Whitney tests for the depression, anxi-
ety, motor hyperactivity and tension items of the BPRS-E
on admission. In these four items of the scale, no signifi-
cant difference between the groups was found (with
alpha level both unadjusted and adjusted by the Holm-
Bonferroni procedure).
Table 3 Sociodemographic and clinical variables across the two ethnic groups
Greeks Non-Greeks 2-sided asymptotic significance
90 58,8% of sample 63 41,2% of sample
Gender: N and % within ethnic group 42 m (46, 7%), 48 f
(53, 3%)
39 m
(61, 9%)
24 f
(38, 1%)
Pearson Chi-Square
Sig. 0,063(ns)
Age Mdn 36 Mean 36.36 SD 10.46
Range19-55
Mdn 34 Mean 35.04 SD10.69
Range:19-59
Mann Whitney
Sig. 0,285(ns)
Smoking status: N and % within ethnic
group
81 yes (90%) 9 no
(10%)
54 yes (85,7%) 9 no
(14,3%)
Pearson Chi-Square
Sig. 0,418(ns)
Forensic status upon admission N and %
within ethnic group
6 yes
(6,7%)
84 no
(93,3%)
0 yes
(0, 0%)
63 no
(100, 0%)
Pearson Chi-Square
Sig. 0,037
Substance abuse on admission N and %
within ethnic group
9 yes (10,0%) 81 no
(90,0%)
12 yes (19,0%) 51 no
(81,0%)
Pearson Chi-Square
Sig. 0,109(ns)
History of substance abuse and % within
ethnic group
21 yes
(23, 3%)
69 no
(76,7%)
15 yes (23, 8%) 48 no
(76, 2%)
Pearson Chi-Square
Sig. 0,946(ns)
Length of stay Mdn 19 Mean20.33 SD 8.46
Range 8-40
Mdn18 Mean 21.81 SD 14.26
Range 5-75
Mann Whitney
Adj. Sig. 0,894(ns)
BPRS improvement Mdn38 Mean 40,16 SD 11,78 Mdn 41 Mean 41,66 SD10,92 Mann Whitney
Adj.Sig. 0,187(ns)
BPRS on admission Mdn 71 Mean 71,97, SD12,15 Mdn 70 Mean 72,95 SD 12,21 Mann Whitney
Adj.Sig. 0,385(ns)
BPRS on discharge Mdn 30, 50 Mean, 31,80 SD 4,24 Mdn 29 Mean 31,29 SD 6,86 Mann Whitney
Adj.Sig. 0,033(ns)
GAF improvement Mdn 25 Mean 26 SD 7,72 Mdn 30 Mean 26,90 SD 10,25 Mann Whitney
Adj.Sig. 0,352(ns)
GAF on admission Mdn 40 Mean 41 SD 8,04 Mdn 40 Mean 41,67 SD 10,12 Mann Whitney
Adj.Sig. 0,760(ns)
GAF on discharge Mdn 70 Mean 67 SD 5,12 Mdn 70 Mean 68,57 SD 6,8 Mann Whitney
Adj.Sig. 0,036(ns)
Polypharmacy on admission Mdn 4 Mean 3,80 SD 1,59 Mdn 4 Mean 3,95 SD 1,22 Mann Whitney Adj.Sig.0,634(ns)
FGAs on admission N and % within ethnic
group
57 yes (63, 3%) 33 no
(36, 7%)
45 yes
(71,4%)
18 no
(28,6%)
Pearson Chi-Square
Adj.Sig.0,296(ns)
SGAs on admission N and % within ethnic
group
81 yes (90,0%) 9 no
(10,0%)
63 yes (100,0) 0 no
(0%)
Pearson Chi-Square
Adj. Sig. 0,011(ns)
SSRIs-SNRIs on admission N and % within
ethnic group
39 yes (43,3%) 51 no
(56,7%)
3 yes (4,8%) 60 no
(95,2%)
Pearson Chi-Square
Sig. 0,000
Fisher’s exact
Sig. 0,000
Mood stabilizers on admission and % within
ethnic group
24 yes (26,7%) 66 no
(73,3%)
12 yes (19,0%) 51 no
(81,0%)
Pearson Chi-Square
Adj. Sig. 0,274(ns)
Benzodiazepines on admission and %
within ethnic group
53 yes
(58, 9%)
37 no
(41,1%)
57 yes (90,5%) 6 no
(9,5%)
Pearson Chi-Square
Sig. 0,000
Fisher’s exact
Sig. 0,000
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Prescribing, in terms of FGAs and SGAs, was not found
to be influenced by ethnicity. These findings are in con-
trast to studies which have revealed lower use of SGAs
among members of American ethnic minority groups
within outpatients suffering from schizophrenia [18-20],
but in agreement with the results of Connolly and Taylor
[5] who focused on in-patients’ use of SGAs. Our find-
ings may suggest that the relationship between in-patient
care and ethnicity might be subject to variables different
than the ones found in outpatient care.
Polypharmacy was not associated with ethnicity. Con-
nolly and Taylor [5] report no differences in antipsycho-
tic polypharmacy with the exception of one centre only.
Covell et al [17] also report no association between poly-
pharmacy and ethnicity. Our finding however cannot be
compared to the latter as a different definition and mea-
sure of polypharmacy was used. Nevertheless, our rate of
polypharmacy will still be associated with a number of
adverse consequences for patients, discussed in Covell et
al. This findings are of significance as polypharmacy was
in the past measured primarily among outpatients
Based on the above, it could be argued that Greek
psychiatrists are not influenced in their prescribing of
antipsychotics by the patient’s ethnicity. Greeks them-
selves have both been immigrants in recent history and
experienced discrimination and prejudice. This history
could act as a sensitizing factor. Moreover, the fact that
Greece has only recently received immigrants can lead
us to the assumption that racial stereotypes have not
been developed as yet. Another explanation is that most
of the immigrants (esp. the ones from the Balkan states)
speak very good Greek and lack of communication diffi-
culties (and skin colour) can account for the lack of
racial bias in some of the patients.
On the other hand, prescribing in terms of SSRIs during
hospitalization was influenced by inpatient ethnicity. Eth-
nic minority group members were less likely to receive
SSRIs. One explanation is that, at the time of the study
generic SSRIs and SNRIs were not widely available in
Greece and their price was not as low as it was in the rest
of Europe. It is only since 2010 that all medication prices
have been substantially reduced and the state has started
putting pressure on doctors to change their prescribing
habits. Contrary to the SSRIs generic SGAs were available
a tt h et i m eo ft h es t u d ya n dw e r eu s e d .O nt h eo t h e r
hand, one cannot dismiss the argument that Greek doctors
SSRIs and SNRIs prescribing for patients with schizophre-
nia, schizoaffective and delusional disorder implies a long
term treatment plan and the absence of it might be an
indication of racist bias. Ethnicity can influence psychiatric
practice in subtle ways [21]. In addition, the significant
lack of studies in terms of SSRI prescribing in terms of
inpatients suggests that further research should be under-
taken. The same applies with regard to mood stabilizers. A
recent survey found longitudinal differences in antimanic
medication use for blacks compared with whites [22].
However, significant absence of previous studies investi-
gating mood stabilizers’ prescribing does not allow com-
parison and thus generalization of findings in this field.
The large difference in benzodiazepines prescribing for
ethnic minority patients cannot be explained by differ-
ences in the BPRS-E items of anxiety, hyperactivity and
tension at baseline. The only plausible explanation for this
finding is that Greek doctors and nurses perceived these
patients as being more agitated and dangerous and felt the
need to sedate them. Research on racial influences on ben-
zodiazepines prescribing is very limited on schizophrenia
inpatients as an indication of racist bias [23]
Our study design had limitations. Firstly, prescribing
doctors were aware that the study protocol of the authors
would relate to prescribing practice. We expected that this
might have been at least in part offset by the fact that all
admitting psychiatrists have their prescriptions reviewed
regularly during the ward rounds. In this respect, their
prescribing is always judged irrespective of any research.
However, the fact that psychiatrists might have been more
conscious of their treatment options remains a weakness
and the chance that this might have biased the results can-
not be dismissed altogether. It is worth emphasizing that
the prescribing doctors were blind to the fact that the
study explored ethnic bias. Secondly, the group members
were not matched for social class or income. This could
have biased the results. It has convincingly been argued
that over representation of certain diagnoses as well as
increased rates of admission among ethnic minority
groups may not be a matter of institutional racism per se
or a matter of overpathologizing bias (i.e. due to misdiag-
nosis owed to the misconception of cultural-specific beha-
vioral cues, as fulfilled diagnostic criteria). Instead, it may
reflect adverse social influences leading to increased levels
of certain mental conditions in members of minorities
[24-26]. McGuire and Miranda [27] provide a very good
discussion on a number of factors which produce clinician
bias and stereotyping, leading to disparities in mental
health practice. Furthermore, our the generalisability of
our study is, to an extent, limited by the fact that the
groups compared were all in-patients in a single urban
hospital. It is also worth noting that non-Greeks were
under-represented in this study.
Conclusions
This was a naturalistic study of psychotropic medication
prescribing in a newly established Psychiatric Clinic in a
General Hospital. We found limited evidence for ethnic
bias in the treatment given. The stronger indication for
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study which investigated ethnic bias in patients involunta-
rily admitted [28] in Greece, Italy and the UK, revealed a
far more controlling and restraining attitude from Greek
psychiatric institutions when compared to Italy and the
UK. Our literature review for this study underlined the
absence of studies assessing prescribing patterns for use
for antidepressants (SSRIs), mood stabilizers, and in parti-
cular for benzodiazepines. This is of interest, again under-
lining the fact that most studies on ethnic bias are related
to schizophrenia in the UK and the US. Racial and ethnic
bias though can be powerfully expressed in the treatment
(or neglect) for other debilitating and distressing psychia-
tric disorders. Ethnicity can influence psychiatric practice
in many, sometimes very subtle ways and future larger-
scale studies focusing on inpatients and outpatients from
less developed economically countries are needed. In par-
ticular, the overall pattern of the findings further suggest
that there is an urgent need for greater-scale research to
investigate racial and/or overpathologizing bias towards
ethnic minority inpatients. Differences between studies
might result as of factors that are expected to be different
within outpatients and inpatients.
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